rare disease biotech
Enhertu Double Approval, Regeneron Miss: What It Means for Smaller Biotechs
Two FDA decisions landed on the same Monday and pulled the sector in opposite directions. AstraZeneca and Daiichi Sankyo’s Enhertu picked up two new approvals in early breast cancer. Regeneron dropped 12% after its melanoma trial missed statistical significance against Keytruda. One validated a platform that smaller biotechs are actively building on. The other confirmed…
One Dose, Months of Relief: Eupraxia’s EoE Breakthrough
Eupraxia Pharmaceuticals (NASDAQ:EPRX) (TSX:EPRX) put out an update on its RESOLVE study this week, and the results look encouraging, at least at this stage. The company shared new tissue and symptom data from patients treated with EP-104GI for eosinophilic esophagitis, a condition that remains difficult to treat long term. What stands out most is how…
